Skip to main content
. 2019 May 3;27(10):1578–1588. doi: 10.1038/s41431-019-0420-7

Table 1.

Frequency of AZFc rearrangements and DAZ dosage alterations in TGCT patients (reported in subgroups based on histotypes and total sperm count) and in controls (reported in subgroups based on total sperm count)

gr/gr deletion Other partial AZFc deletionsa Partial AZFc duplications DAZ dosage alteration
TGCT Total 14/497 (2.8%) 5/497 (1.0%) 22/478 (4.6%) 51/497 (10.3%)
NZ 9/268 (3.4%) 3/268 (1.1%) 9/256 (3.5%) 28/268 (10.4%)
NNZ 5/229 (2.2%) 2/229 (0.9%) 13/222 (5.9%) 23/229 (10.0%)
Seminoma 11/353 (3.1%) 4/353 (1.1%) 16/338 (4.7%) 38/353 (10.8%)
Non-seminoma 3/144 (2.1%) 1/144 (0.7%) 6/140 (4.3%) 13/144 (9.0%)
Seminoma NZ 8/196 (4.1%) 2/196 (1.0%) 7/186 (3.8%) 23/196 (11.7%)
Seminoma NNZ 3/157 (1.9%) 2/157 (1.3%) 9/152 (5.9%) 15/157 (9.5%)
Non-Seminoma NZ 1/72 (1.4%) 1/72 (1.4%) 2/70 (2.9%) 5/72 (6.9%)
Non-Seminoma NNZ 2/72 (2.8%) 0/72 (0.0%) 4/70 (5.7%) 8/72 (11.1%)
Controls Total 40/2030 (2.0%) 11/2030 (0.5%) 51/1373 (3.7%) 111/1424 (7.8%)
NZ 10/1068 (0.9%) 2/1068 (0.2%) 27/756 (3.6%) 46/768 (6.0%)
NNZ 30/962 (3.1%) 9/962 (0.9%) 24/617 (3.9%) 65/656 (9.9%)

The columns report the number of subject observed with rearrangements/total subject patients and the percentage in parenthesis

NZ normozoospermic, NNZ non-normozoospermic

aOther partial AZFc deletions refers to b2/b3, b1/b3, and atypical deletion